Published in Oncoimmunology on February 07, 2017
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J (1995) 3.78
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood (1997) 3.08
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol (2014) 2.59
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res (2010) 1.66
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med (2015) 1.58
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol (2016) 1.54
Balancing natural killer cell activation through paired receptors. Nat Rev Immunol (2015) 1.44
An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med (1998) 1.36
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res (2013) 1.36
The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. Nat Immunol (2013) 1.26
Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med (2000) 1.24
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med (2014) 1.21
CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling. J Biol Chem (1999) 1.21
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res (2014) 1.19
NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci U S A (2015) 1.14
Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 1.06
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat Commun (2014) 1.03
Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol (2015) 1.02
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discov (2016) 0.92
Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest (2015) 0.86
The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity. Oncoimmunology (2013) 0.81
Natural Killer cell control of BRAF(V600E) mutant melanoma during targeted therapy. Oncoimmunology (2015) 0.80
Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis. Oncoimmunology (2015) 0.78